Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NBL-028 in Advanced Solid Tumors
NCT06223256Phase 1Recruiting
- Sponsor
- NovaRock Biotherapeutics
- Start
- Mar 2024
- Primary completion
- Jan 2027
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of NBL-028 in solid tumor (advanced stage), sponsored by NovaRock Biotherapeutics. Primary endpoints: Dose-limiting toxicity at 1 year, Adverse Events and Serious Adverse Events at 3 years and 2 more. Started Mar 2024; status: recruiting.
02
Drugs
NBL-028
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT06223256.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06223256.